Company Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases.
Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases.
The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy.
The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014.
Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
| Country | United States |
| Founded | 2004 |
| IPO Date | May 2, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Dr. Todd C. Brady M.D., Ph.D. |
Contact Details
Address: 131 Hartwell Avenue, Suite 320 Lexington, Massachusetts 02421 United States | |
| Phone | 781-761-4904 |
| Website | aldeyra.com |
Stock Details
| Ticker Symbol | ALDX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001341235 |
| CUSIP Number | 01438T106 |
| ISIN Number | US01438T1060 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd C. Brady M.D., Ph.D. | Chief Executive Officer, President and Director |
| Bruce Greenberg CPA, M.B.A. | Senior Vice President of Finance, Interim Chief Financial Officer and Treasurer |
| Dr. Stephen G. Machatha Ph.D. | Chief Development Officer |
| Kelly Mizer | Vice President of Commercial Strategy and Operations |
| David Burke | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2024 | 8-K | Current Report |
| Jun 13, 2024 | 8-K | Current Report |
| Jun 7, 2024 | 8-K | Current Report |
| May 2, 2024 | 10-Q | Quarterly Report |
| Apr 25, 2024 | 8-K | Current Report |
| Apr 24, 2024 | EFFECT | Notice of Effectiveness |
| Apr 22, 2024 | ARS | Filing |
| Apr 22, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 22, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 28, 2024 | 8-K | Current Report |